Which regulatory risks go unnoticed in life sciences acquisitions until they put the deal at risk?

Regulatory risks in life sciences follow a sequence logic that purely legal and financial reviews fail to capture: first, the marketing-authorization status determines market access, because a product whose certificate under the superseded MDD 93/42/EWG is expiring and that has not been transferred to the MDR (EU 2017/745) loses its revenue regardless of how clean the balance sheet looks. Only after that does the quality management system to ISO 13485:2016 carry ongoing compliance, and this is where the real bottleneck lies: a valid certificate says nothing about CAPA backlog, deviation trends or open major findings, that is, precisely the items whose remediation blows up the integration plan. Finally, the authority history, from open Warning Letters to critical statements, feeds back into both levels.

It is exactly this sequence that determines which finding becomes purchase-price-relevant: a single open CAPA item is effort, an incomplete transition path for a revenue-bearing product is a value lever. That is why we do not merely condense the findings but monetize them, separating the expensive remediation that is still negotiable before signing from the rest, which has to be secured through an integration budget or escrow. The red-flag report maps this distinction so the deal team knows the levers while they still exist.